Evidence map›Paper›PMID 40222937›Full record

ArticleInternal medicine (Tokyo, Japan)2025

Salvage HLA-haploidentical Peripheral Blood Stem Cell Transplantation Using Post-transplant Cyclophosphamide for Recurrent Hemophagocytic Lymphohistiocytosis-associated Graft Failure after Cord Blood Transplantations.

Keijiro Sato, Wataru Komaba, Saika Oka, Shintaro Kazama, Ryuto Ishikawa, Takahiro Morikawa, Mari Kitahara, Hiroko Kazumoto, Hiroko Kaiume, Toshimitsu Ueki and 3 more

Abstract readCase Reports
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Keijiro SatoDepartment of Hematology, Nagano Red Cross Hospital, Japan.
Wataru KomabaDepartment of Hematology, Nagano Red Cross Hospital, Japan.
Saika OkaDepartment of Hematology, Nagano Red Cross Hospital, Japan.
Shintaro KazamaDepartment of Hematology, Nagano Red Cross Hospital, Japan.
Ryuto IshikawaDepartment of Hematology, Nagano Red Cross Hospital, Japan.
Takahiro MorikawaDepartment of Hematology, Nagano Red Cross Hospital, Japan.
Mari KitaharaDepartment of Hematology, Nagano Red Cross Hospital, Japan.
Hiroko KazumotoDepartment of Hematology, Nagano Red Cross Hospital, Japan.
Hiroko KaiumeDepartment of Hematology, Nagano Red Cross Hospital, Japan.
Toshimitsu UekiDepartment of Hematology, Nagano Red Cross Hospital, Japan.
Yuki HiroshimaDepartment of Hematology, Nagano Red Cross Hospital, Japan.
Masahiko SumiDepartment of Hematology, Nagano Red Cross Hospital, Japan.
Hikaru KobayashiDepartment of Hematology, Nagano Red Cross Hospital, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We describe a case of immunological rejection occurring twice after cord blood transplantation (CBT) for mixed phenotype blast phase chronic myeloid leukemia that was successfully salvaged by haploidentical peripheral blood stem cell transplantation (haplo-PBSCT) with post-transplant cyclophosphamide (PT-Cy). Pre-engraftment immune reaction (PIR) and subsequent hemophagocytic lymphohistiocytosis (HLH), likely due to HLA mismatch in the graft-versus-host (GVH) direction, lead to poor graft function (PGF) and graft failure (GF). This case highlights the pathophysiology of PIR, HLH, PGF, and GF, collectively termed "post-transplant cytokine syndrome." PT-Cy haplo-PBSCT, with wide donor availability and reduced infection risk leading to HLH via rapid engraftment, may be a suitable salvage option for post-CBT cytokine syndrome-related GF.

Indexed as

Cord Blood Stem Cell TransplantationCyclophosphamideGraft RejectionLymphohistiocytosis, HemophagocyticPeripheral Blood Stem Cell TransplantationSalvage TherapyFemaleGraft vs Host DiseaseHLA AntigensHumansImmunosuppressive AgentsMaleRecurrenceTransplantation, HaploidenticalCyclophosphamideHLA AntigensImmunosuppressive Agentscord blood transplantationgraft failurehemophagocytic lymphohistiocytosisHLA-haploidentical transplantationpost-transplant cyclophosphamide

Identifiers

PMID40222937
PMCPMC12589169

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.